# Phase II Study of Single Agent Lenvatinib

> **NCT03168074** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lenvatinib

## Key facts

- **NCT ID:** NCT03168074
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-28
- **Primary completion:** 2021-03-28
- **Final completion:** 2021-03-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-06-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168074, "Phase II Study of Single Agent Lenvatinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03168074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*